Global Information
회사소개 | 문의 | 비교리스트

비알코올성 지방간염(NASH) : 역학 예측(-2029년)

Non-Alcoholic Steatohepatitis - Epidemiology Forecast to 2029

리서치사 GlobalData
발행일 2020년 06월 상품 코드 944086
페이지 정보 영문 35 Pages
가격
US $ 3,995 ₩ 4,719,000 PDF by E-mail (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,990 ₩ 9,438,000 PDF by E-mail (Site License) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 11,985 ₩ 14,157,000 PDF by E-mail (Global License) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


비알코올성 지방간염(NASH) : 역학 예측(-2029년) Non-Alcoholic Steatohepatitis - Epidemiology Forecast to 2029
발행일 : 2020년 06월 페이지 정보 : 영문 35 Pages

세계 주요 7개국(미국, 일본, 영국, 독일, 프랑스, 스페인, 이탈리아)의 비알코올성 지방간염(NASH) 진단 증례는 2019년 2,612만 4,484건에서 2029년 3,413만 9,592건으로 향후 10년간 3.07%의 성장률로 증가할 전망입니다. GlobalData의 조사에 의하면 침습성 낮은 진단 방법의 개발, 의사의 인식 향상, 스크리닝 프로그램 실시에 의해 총증례수와 진단 유병률 증례수가 보다 많아질 가능성이 있다고 예측하고 있습니다. 또한 유전자 연구에서는 PNPLA3 다형이 NAFLD, 즉 NASH와 강한 관련성이 있는 것으로 나타나 향후 연구 분야가 되고 있습니다.

세계의 비알코올성 지방간염(NASH)에 대해 조사했으며, 질환 개요, 향후 동향 예측, 헬스케어 사업 전략 등의 정보를 제공합니다.

목차

제1장 목차

  • 표 리스트
  • 그림 리스트

제2장 조사 개요

제3장 역학

  • 질병 배경
  • 위험인자와 병존증
  • 세계 및 과거 동향
    • NASH 총유병율
    • NASH 진단된 유병률
  • 예측 조사 방법
    • 정보
    • 사용되지 않은 정보
    • 예측 가정과 방법
    • NASH 유병례 합계
    • NASH 진단된 유병례
    • 섬유증 병기별 NASH 진단 유병례
  • NASH 역학 예측(2019-2029년)
    • 유병례 합계
    • 진단 유병례
    • 연령별
    • 성별
    • 섬유증 병기별 NASH 진단 유병례
  • 논의
    • 역학 예측 인사이트
    • 분석 제한
    • 분석 강점

제4장 부록

  • 참고문헌
  • 1차 조사 : 처방자 조사
  • 저자 소개
    • 역학자
    • 검토자
    • 치료 분석 및 역학의 세계 디렉터
    • 헬스케어 사업·전략 : 세계의 선도자 및 EVP
  • GlobalData 소개
  • 문의
  • 면책사항
KSM 20.07.10

List of Tables

List of Tables

  • Table 1: Summary of Newly Added Data Types
  • Table 2: Risk Factors and Comorbidities for NASH
  • Table 3: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
  • Table 4: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

List of Figures

  • Figure 1: 7MM, Total Prevalent Cases of NASH, Both Sexes, 2019 and 2029
  • Figure 2: 7MM, Diagnosed Prevalent Cases of NASH, Both Sexes, 2019 and 2029
  • Figure 3: 7MM, Total Prevalence of NASH (%), Both Sexes, All Ages, 2009*2029
  • Figure 4: 7MM, Diagnosed Prevalence of NASH (%), Both Sexes, All Ages, 2009*2029
  • Figure 5: 7MM, Sources Used for NASH Total Prevalence
  • Figure 6: 7MM, Sources Used for Obesity Prevalence
  • Figure 7: 7MM, Sources Used for the Diagnosed Prevalent Cases of NASH and Diagnosed Prevalent Cases of NASH by Stage of Fibrosis
  • Figure 8: 7MM, Total Prevalent Cases of NASH, Both Sexes, All Ages, 2019
  • Figure 9: 7MM, Diagnosed Prevalent Cases of NASH, Both Sexes, All Ages, 2019
  • Figure 10: 7MM, Age-Specific Diagnosed Prevalent Cases of NASH, Both Sexes, 2019
  • Figure 11: 7MM, Sex-Specific Diagnosed Prevalent Cases of NASH, All Ages, 2019
  • Figure 12: 7MM, Diagnosed Prevalent Cases of NASH by Stage of Fibrosis, Both Sexes, All Ages, 2019

Non-alcoholic steatohepatitis (NASH) is a common, often clinically silent liver disease characterized by the presence of steatosis (fatty liver), in addition to liver inflammation and damage (NIDDK, 2016). Unlike alcoholic liver disease, NASH occurs in those who drink little or no alcohol. NASH usually presents with few or no symptoms, and most people affected with the disease feel healthy and are unaware they have a problem (NIDDK, 2016).

GlobalData epidemiologists utilized primary research and comprehensive, country-specific data from peer-reviewed journal articles when available, to arrive at a meaningful, in-depth analysis and forecast for the total and diagnosed prevalent cases of NASH. For all the 7MM, NASH cases were segmented by age and sex, and were then further segmented by NASH stage of fibrosis. Since obesity is a major risk factor for NASH, the historical, country-specific prevalence trends in obesity were incorporated to determine the prevalence trends in NASH.

GlobalData epidemiologists forecast that the total prevalent cases of NASH in the 7MM will grow by an annual growth rate (AGR) of 0.55% over the next 10 years, from 68,302,915 cases in 2019 to 72,059,723 cases in 2029. For diagnosed prevalent cases, GlobalData epidemiologists forecast that the 7MM will grow by an AGR of 3.07% over the next 10 years, from 26,124,484 cases in 2019 to 34,139,592 cases in 2029. For the stage of fibrosis in 2019, stages F0-F1 were the most common stages, representing 30.47% of diagnosed prevalent cases of NASH. GlobalData epidemiologists expect that the development of less-invasive diagnostic methods, increased physician awareness, and screening programs may drive the number of total and diagnosed prevalent cases higher. Additionally, genetic research has shown that PNPLA3 polymorphisms have a strong association with NAFLD, and therefore NASH, making it a future area of study.

Scope

  • The Non-Alcoholic Steatohepatitis Epidemiology Report provides an overview of the risk factors, comorbidities, and global trends of Non-Alcoholic Steatohepatitis (NASH) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report includes a 10-year epidemiological forecast for the total prevalent cases (both diagnosed and undiagnosed) of NASH segmented by age (0-17 years, 18-29, and by 10-year age groups up to 80 years and older) and sex. It also includes a 10-year epidemiological forecast for the diagnosed prevalent cases of NASH, which are further segmented by stage of fibrosis (F0-F1, F2, F3, and F4). In addition, the epidemiology model corresponding to this report provides the total and diagnosed prevalent cases of NAFLD in ages 18 years and older.
  • The NASH epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to Buy

  • The NASH Epidemiology series will allow you to:
  • Develop business strategies by understanding the trends shaping and driving the global NASH markets.
  • Quantify patient populations in the global NASH markets to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for NASH therapeutics in each of the markets covered.
  • Understand magnitude of NASH population by stage of fibrosis.

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Non-Alcoholic Steatohepatitis: Executive Summary

  • 2.1 Catalyst
  • 2.2 Related Reports
  • 2.3 Upcoming Reports

3 Epidemiology

  • 3.1 Disease Background
  • 3.2 Risk Factors and Comorbidities
  • 3.3 Global and Historical Trends
    • 3.3.1 Total Prevalence of NASH (%)
    • 3.3.2 Diagnosed Prevalence of NASH (%)
  • 3.4 Forecast Methodology
    • 3.4.1 Sources
    • 3.4.2 Sources Not Used
    • 3.4.3 Forecast Assumptions and Methods
    • 3.4.4 Total Prevalent Cases of NASH
    • 3.4.5 Diagnosed Prevalent Cases of NASH
    • 3.4.6 Diagnosed Prevalent Cases of NASH by Stage of Fibrosis
  • 3.5 Epidemiological Forecast for NASH (2019-2029)
    • 3.5.1 Total Prevalent Cases of NASH
    • 3.5.2 Diagnosed Prevalent Cases of NASH
    • 3.5.3 Age-Specific Diagnosed Prevalent Cases of NASH
    • 3.5.4 Sex-Specific Diagnosed Prevalent Cases of NASH
    • 3.5.5 Diagnosed Prevalent Cases of NASH by Stage of Fibrosis
  • 3.6 Discussion
    • 3.6.1 Epidemiological Forecast Insight
    • 3.6.2 Limitations of the Analysis
    • 3.6.3 Strengths of the Analysis

4 Appendix

  • 4.1 Bibliography
  • 4.2 Primary Research - Prescriber Survey
  • 4.3 About the Authors
    • 4.3.1 Epidemiologist
    • 4.3.2 Reviewers
    • 4.3.3 Global Director of Therapy Analysis and Epidemiology
    • 4.3.4 Global Head and EVP of Healthcare Operations and Strategy
  • 4.4 About GlobalData
  • 4.5 Contact Us
  • 4.6 Disclaimer
Back to Top
전화 문의
F A Q